ECRG2 Antibody
- 产品详情
- 实验流程
- 背景知识
Application
| WB, E, IHC-P |
|---|---|
| Primary Accession | P58062 |
| Other Accession | AAI09386, 14211875 |
| Reactivity | Human, Mouse, Rat |
| Host | Chicken |
| Clonality | Polyclonal |
| Isotype | IgY |
| Calculated MW | 9232 Da |
| Concentration (mg/ml) | 1 mg/mL |
| Conjugate | Unconjugated |
| Application Notes | ECRG2 antibody can be used for detection of ECRG2 by Western blot at 1 µg/mL. Antibody can also be used for immunohistochemistry starting at 5 µg/mL. |
| Gene ID | 84651 |
|---|---|
| Other Names | Serine protease inhibitor Kazal-type 7, Esophagus cancer-related gene 2 protein, ECRG-2, SPINK7, ECG2 |
| Target/Specificity | SPINK7; ECRG2 antibody is predicted to not cross-react with other ECRG family members |
| Reconstitution & Storage | ECRG2 antibody can be stored at 4℃ for three months and -20℃, stable for up to one year. As with all antibodies care should be taken to avoid repeated freeze thaw cycles. Antibodies should not be exposed to prolonged high temperatures. |
| Precautions | ECRG2 Antibody is for research use only and not for use in diagnostic or therapeutic procedures. |
For Research Use Only. Not For Use In Diagnostic Procedures.
| Name | SPINK7 |
|---|---|
| Synonyms | ECG2 |
| Function | Probable serine protease inhibitor. |
| Cellular Location | Secreted. |
Provided below are standard protocols that you may find useful for product applications.
BACKGROUND
ECRG2 Antibody: The esophageal cancer-susceptibility gene 2 (ECRG2), also known as SPINK7, is a novel tumor suppressor gene identified from the human esophagus. It interacts directly with metallothionein 2A and urokinase-type plasminogen activator (uPA), and downregulates the activity of uPA, leading to reduced cancer cell migration, invasion and metastasis. ECRG2 forms a complex with uPA and its receptor uPAR, modifying the dynamic association of uPAR with beta1 integrins and disrupting the Src/MAP kinase pathway that normally stimulates cell migration and invasion. ECRG2 may thus represent a novel therapeutic target for cancer.
REFERENCES
Cui Y, Wang J, Zhang X, et al. ECRG2, a novel candidate of tumor suppressor gene in the esophageal carcinoma, interacts directly with metallothionein 2A and links to apoptosis. Biochem. Biophys. Res. Commun. 2003; 302:904-15.
Huang G, Hu Z, Li M, et al. ECRG2 inhibits cancer cell migration, invasion and metastasis through the down-regulation of uPA/plasmin activity. Carcinogenesis 2007; 28:2274-81
Cheng X, Shen Z, Yin L, et al. ECRG2 regulates cell migration/invasion through the urokinase-type plasmin activator receptor (uPAR)/beta1 integrin pathway. J. Biol. Chem. 2009; 284:30897-906
终于等到您。ABCEPTA(百远生物)抗体产品。
点击下方“我要评价 ”按钮提交您的反馈信息,您的反馈和评价是我们最宝贵的财富之一,
我们将在1-3个工作日内处理您的反馈信息。
如有疑问,联系:0512-88856768 tech-china@abcepta.com.
















癌症的基本特征包括细胞增殖、血管生成、迁移、凋亡逃避机制和细胞永生等。找到癌症发生过程中这些通路的关键标记物和对应的抗体用于检测至关重要。
为您推荐一个泛素化位点预测神器——泛素化分析工具,可以为您的蛋白的泛素化位点作出预测和评分。
细胞自噬受体图形绘图工具为你的蛋白的细胞受体结合位点作出预测和评分,识别结合到自噬通路中的蛋白是非常重要的,便于让我们理解自噬在正常生理、病理过程中的作用,如发育、细胞分化、神经退化性疾病、压力条件下、感染和癌症。